Embla Medical – Presentation of Q1 2025 interim report
You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.
Embla Medical will release its Q1 2025 interim report on 29 April 2025. The same day at 10.30 AM, the company’s management will present the results and answer questions in an online live event. We expect a presentation of the financial results and an update on the recent business and regulatory developments.
In 2025, the company expects organic growth between 5-8%, with 6% realized in 2024. Growth is primarily expected to be driven by new product launches in the Bionic series, impacts from the expansion of the US Medicare Coverage, and leverage of the Fior & Gentz acquisition with the roll-out of their offerings to new markets. The EBITDA margin with guidance of 20-21% vs. 20% realized in 2024 is expected to improve (mid-range). Besides topline growth, margins are expected to be positively impacted by positive product mix effects from increased sales in high-end solutions, as well as continued efficiency gains in manufacturing.
Besides the financial Q1 25 results and how they track vs. the full year guidance, focus could be on comments on the potential of tariffs, as the 2025 guidance doesn’t include any potential negative effects from changes here.
Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics & Neuro Orthotics, Bracing & Supports, and Patient Care.
Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 11.27 AM, 31-03-2025.
